Chembio (NASDAQ:CEMI) is a diagnostic company with a focus on developing and marketing point of care tests. Since 2008, the company's revenues have grown significantly as it has penetrated international markets, developed new technology and worked with its U.S. partner, Alere (NYSE:ALR), to gain share.
(click to enlarge)
Despite the impressive run up in sales, stock performance has been disappointing over the past year. Up to March of this year, it looked as if the company's shares were on a roll (with the rest of the market). Then two events happened. First, the company reported its fourth quarter 2012 results on March 7. Despite sales in the quarter being 18% higher than in any other quarter...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|